Table 1 comparison of patient groups in the pre-intervention and post-intervention study periods
Control period | Intervention (AXDX) period | P value | |||
|---|---|---|---|---|---|
N | 46 | 57 | |||
Time period | 26.2.20–11.7.20 | 28.7.20–21.2.21 | |||
Age, median (IQR) | 79 (65–84) | 75 (68–82) | 0.28 | ||
Inclusion criteria | Age > 70, N (%) | 32 (73%) | 40 (70%) | 0.83 | |
Previous hospitalization, N (%) | 25 (54%) | 37 (65%) | 0.32 | ||
Previous antimicrobial treatment, N (%) | 23 (50%) | 36 (63%) | 0.23 | ||
Long term care facility residence, N (%) | 9 (20%) | 14 (25%) | 0.64 | ||
Immunosuppression, N (%) | 10 (22%) | 6 (11%) | 0.17 | ||
Intensive care unit admission, N (%) | 7 (15%) | 7 (12%) | 0.78 | ||
Charlson comorbidity index, median (IQR) | 6 (5–8) | 6 (4–8) | 0.74 | ||
Pitt bacteremia score, median (IQR) | 2 (0–4) | 2 (0–4) | 0.95 | ||
Infection source | Urinary | 24 (52%) | 29 (51%) | > 0.99 | |
Non urinary | 22 (48%) | 28 (49%) | |||
Respiratory | 4 (9%) | 2 (4%) | |||
Abdominal | 10 (21%) | 7 (12%) | |||
Intravascular catheter | 4 (9%) | 7 (12%) | |||
Surgical site | 0 (0%) | 1 (2%) | |||
Other | 3 (6%) | 5 (9%) | |||
Unknown | 1 (2%) | 6 (11%) | |||
Bacteria | Enterobacterales | Ceftriaxone sensitive | 21/39 | 32/51 | |
Ceftriaxone resistant | 17/39 | 17/51 | 0.38 (vs. sensitive) | ||
Carbapenem resistant | 1/39 | 2/51 | > 0.99 (vs. non-CRE) | ||
E. coli | 25 | 27 | |||
Klebsiella | 7 | 14 | |||
Other Enterobacterales | 9 | 10 | |||
Non-fermenters | Pseudomonas aeruginosa | 3 | 5 | ||
Acinetobacter baumanii – carbapenem sensitive | 0 | 2 | |||
Acinetobacter baumanii – carbapenem resistant | 2 | 1 | |||
Other | 1 | 3 | |||
Polymicrobial bacteremia, N (%) | 2 (4%) | 6 (11%) | 0.29 |